Compounds and their pharmaceutically acceptable salts for treatment of tauopathies, such as Alzheimer's disease, Pick's disease, progressive supranuclear palsy, corticobasal degeneration, familial frontotemporal dementia/Parkinsonism linked to chromosome 17, amyotrophic lateral sclerosis/Parkinsonism-dementia complex, argyrophilic grain dementia, dementia pugilistic, diffuse neurofibrillary tangles with calcification, progressive subcortical gliosis and tangle only dementia.

Compounds and their pharmaceutically acceptable salts for treatment of tauopathies, such as Alzheimer's disease, Pick's disease, progressive supranuclear palsy, corticobasal degeneration, familial frontotemporal dementia/Parkinsonism linked to chromosome 17, amyotrophic lateral sclerosis/Parkinsonism-dementia complex, argyrophilic grain dementia, dementia pugilistic, diffuse neurofibrillary tangles with calcification, progressive subcortical gliosis and tangle only dementia.

The present specification provides a compound having a spiro structure, and an organic light emitting device including the same.

The present specification provides a compound having a spiro structure, and an organic light emitting device including the same.

The present disclosure is directed to use of MrgprX2 antagonists in the treatment of inflammatory disorders, e.g., inflammatory disorders of the skin. This invention is also directed to pharmaceutical compositions comprising a MrgprX2 antagonist and a pharmaceutically acceptable carrier for topical or oral administration.

The present disclosure is directed to use of MrgprX2 antagonists in the treatment of inflammatory disorders, e.g., inflammatory disorders of the skin. This invention is also directed to pharmaceutical compositions comprising a MrgprX2 antagonist and a pharmaceutically acceptable carrier for topical or oral administration.

An electrolyte solution additive, an electrolyte solution including the same, and a lithium secondary battery including the same are disclosed herein. In some embodiments, an electrolyte solution additive includes a compound represented by Formula 1:

##STR00001##

Wherein X is oxygen (O) or sulfur (S), and R is a substituted or unsubstituted alkyl group having 1 to 5 carbon atoms or N(R.sub.1).sub.2, wherein R.sub.1 is hydrogen or a substituted or unsubstituted alkyl group having 1 to 5 carbon atoms. The additive has an excellent effect of scavenging a decomposition product generated from a lithium salt and simultaneously forming a robust film on a surface of a positive electrode.

An electrolyte solution additive, an electrolyte solution including the same, and a lithium secondary battery including the same are disclosed herein. In some embodiments, an electrolyte solution additive includes a compound represented by Formula 1:

##STR00001##

Wherein X is oxygen (O) or sulfur (S), and R is a substituted or unsubstituted alkyl group having 1 to 5 carbon atoms or N(R.sub.1).sub.2, wherein R.sub.1 is hydrogen or a substituted or unsubstituted alkyl group having 1 to 5 carbon atoms. The additive has an excellent effect of scavenging a decomposition product generated from a lithium salt and simultaneously forming a robust film on a surface of a positive electrode.

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

The present invention generally discloses compounds having LXR (the liver X receptor) agonistic activity, to the use of such compounds in the treatment of various disorders such as proliferative disorders, Alzheimer's disease, inflammatory diseases, and diseases characterized by defects in cholesterol and lipid metabolism. Specifically, the present invention discloses compound of formula (IA) which exhibit LXR agonist activity, specifically to LXRβ. The invention also discloses method of synthesis of said compounds, method of using said compounds, pharmaceutical compositions comprising said compounds and method of using thereof.

##STR00001##